Skip to main content

uniQure to Participate in Multiple Upcoming Industry Conferences in April

Written by Customer Service on . Posted in Public Companies.

LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

  • Virtual Guggenheim Healthcare Talks│2021 Genomic Medicines & Rare Disease, April 1, 2021
    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Thursday, April 1.
    • Matt Kapusta, chief executive officer, will participate on a panel discussion entitled, “The Low-Hanging Fruit in Gene Therapy Might Be Hard to Reach – Challenges for Hemophilia A and B” on Thursday, April 1 from 10:00 to 10:50 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    • Ricardo Dolmetsch, Ph.D., president of research and development, will participate in a panel discussion entitled, “An Idea Whose Time has Come – Disease Modifying Therapies for Huntington’s Disease” later the same day from 3:00 to 3:50 p.m. ET.
  • Wells Fargo Corporate Access Days, April 6-8, 2021
    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, April 6.
  • Professional Patient Advocates in Life Sciences, April 13, 2021
    • Daniel Leonard, senior director of global patient advocacy, will participate on a virtual panel discussion entitled, “Building an Internal Patient Advocacy & HR Relationship Series – Part 1: Journey to Patient Advocacy” starting at 2:00 p.m. ET on Tuesday, April 13.
  • 20thAnnual Needham Virtual Healthcare Conference, April 12 – 15, 2021
    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Thursday, April 15.
    • A company presentation with Matt Kapusta will take place the same day from 3:45 to 4:25 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
  • Chardan 5thAnnual Genetic Medicines Manufacturing Summit, April 26 – 27, 2021
    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings on Tuesday, April 27.
    • A fireside chat with Matt Kapusta will take place the same day from 1:45 to 2:25 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
  • Kempen Life Sciences Conference – 2021 Thematic Virtual Series “Cell, Gene & RNA based companies,” April 28, 2021
    • Members of uniQure’s management team will participate in virtual one-on-one investor meetings on Wednesday, April 28.
  • CHDI’s 16thAnnual Huntington’s Disease Therapeutics Conference, April 27-29, 2021
    • David Cooper, M.D., vice president of clinical research CNS, will present in the clinical stage interventional programs session on Thursday, April 29 between 10:00 a.m. and 12:30 p.m. ET. His presentation is entitled, “Updates on HD-GeneTRX-1: A Phase 1-2 Clinical Trial of CNS-Administered Gene Therapy (AMT-130) for Early-Stage HD.” Following the pre-recorded presentation, Dr. Cooper will be available for live Q&A.
    • Astrid Valles-Sanchez, Ph.D., senior scientist at uniQure, will have a poster presentation entitled, “Lowering the Pathogenic Exon1 HTT Fragment by AAV5-miHTT Gene Therapy,” during the conference dates.
  • World Orphan Drug Congress, April 28, 2021
    • Nick Li, Ph.D., M.B.A., senior director, global/US market access lead, will participate on a panel entitled “Pricing & Reimbursement for Rare Diseases in the United States” starting at 3:00 p.m. ET on Wednesday, April 28.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington’s disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.